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Authors’ reply
Tom Peto and colleagues point out, 
reasonably, that the effect of mass 
drug administration (MDA) on malaria 
could be affected substantially by 
patterns of human movement, and 
that our Article1 does not consider 
the effects of the specific patterns of 
movement they observed in Cambodia 
and west Africa. The purpose of 
our Article1 was to derive general 
results about the possible effect of 
MDA and to test how robust these 
are to the assumptions in different 
models, so we avoided assumptions 
about population movement that 
are specific to any particular place. 
Migration is among several factors 
that the different groups in our 
collaboration have investigated as 
potential modifiers of the effects of 
mass treatment in specific situations. 
For those analyses, we have used 
field data or realistic assumptions of 
migration rates.2–4 Human migration 
is a particularly complicated modifier; 
the endemicity of malaria in the places 
from which immigrants or temporary 
visitors originate could be important, 
not just the season and extent of 
migration. 
A thorough empirical investigation 
of the implications of different 
patterns of migration for the 
effect of MDA would require a 
prohibitively complex set of field 
trials. Corresponding in silico analyses, 
parameterised with local field data, 
are more feasible but still represent 
an extensive piece of research in their 
own right, which is well beyond the 
scope of our Article.1 Some of our 
research groups use extensive field 
data collection for this exact purpose.5 
The questions addressed in our Article1 
were raised by WHO for their Evidence 
Review Group on mass treatment 
of malaria, which contains many 
experts who work directly on MDA 
interventions. Furthermore, several 
ongoing modelling exercises are 
being carried out by the authors of our 
Article1 in collaboration with control 
programmes to assess the potential 
effect of MDA in specific settings.6 
We agree with Peto and colleagues on 
the importance of modelling groups 
and field researchers working closely 
together to better inform models and 
improve predictions of intervention 
outcomes. Involvement of modellers 
in trial design and operational 
planning for specific interventions 
allows questions to be framed as 
accurately as possible for relevant 
geographies and broader policy 
recommendations, and we hope that 
the number of these exercises will 
increase in the coming years.
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